Literature DB >> 21331599

Dyslipidaemia in chronic acquired distal axonal polyneuropathy.

Yusuf A Rajabally1, Rahul S Shah.   

Abstract

The link between hypertriglyceridaemia (HTG) and/or hypercholesterolaemia (HCL) and neuropathy is uncertain. We retrospectively reviewed records of 100 consecutive patients investigated for acquired chronic axonal distal polyneuropathy of unknown cause. Findings were compared with those of 102 consecutive controls. Patients with idiopathic neuropathy were subsequently compared with age- and gender-matched controls. There were more neuropathy patients than controls with HCL, defined as cholesterol levels >5 mmol/L (63 vs. 45.1%; p = 0.011). Neuropathy patients also had higher cholesterol levels than controls (p = 0.04). Cholesterol-lowering drug usage was similar in both groups. HTG (defined as >2 mmol/L) and triglyceride levels were comparable in both groups. HTG ranged from 2.1-4.2 mmol/L in neuropathy patients. A cause for neuropathy was identified in 59 patients. Thirty-one had impaired glucose metabolism. Forty-one had idiopathic neuropathy. No link was demonstrated between idiopathic neuropathy or painful idiopathic neuropathy, and HTG/HCL. Mean triglyceride and cholesterol levels in patients with idiopathic neuropathy were comparable to those of controls. HTG was significantly more common (p = 0.027), and triglyceride levels significantly higher (p = 0.005) in patients with neuropathy due to diabetes/impaired glucose tolerance (IGT)/alcoholism, than in patients with neuropathy of any other cause. These results suggest HCL >5 mmol/L may represent a cofactor contributing to presence of neuropathy irrespective of the underlying cause. They on the other hand do not support mild/moderate HTG as an independent cause of neuropathy. HTG is common in patients with neuropathy associated with diabetes/IGT/chronic alcoholism, where it may play a role in peripheral nerve damage. As previously reported, IGT was in our cohort frequent, present in one case in three, in the absence of another identifiable aetiology.

Entities:  

Mesh:

Year:  2011        PMID: 21331599     DOI: 10.1007/s00415-011-5950-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.

Authors:  J R Singleton; A G Smith; M B Bromberg
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

3.  Peripheral neuropathy in young-old and old-old patients.

Authors:  J Verghese; P L Bieri; C Gellido; H H Schaumburg; S Herskovitz
Journal:  Muscle Nerve       Date:  2001-11       Impact factor: 3.217

Review 4.  Neuropathy and impaired glucose tolerance: an updated review of the evidence.

Authors:  Y A Rajabally
Journal:  Acta Neurol Scand       Date:  2010-09-26       Impact factor: 3.209

5.  Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy.

Authors:  Charlene Hoffman-Snyder; Benn E Smith; Mark A Ross; Jose Hernandez; E Peter Bosch
Journal:  Arch Neurol       Date:  2006-06-12

6.  Vascular risk factors and diabetic neuropathy.

Authors:  Solomon Tesfaye; Nish Chaturvedi; Simon E M Eaton; John D Ward; Christos Manes; Constantin Ionescu-Tirgoviste; Daniel R Witte; John H Fuller
Journal:  N Engl J Med       Date:  2005-01-27       Impact factor: 91.245

7.  Statins and risk of polyneuropathy: a case-control study.

Authors:  D Gaist; U Jeppesen; M Andersen; L A García Rodríguez; J Hallas; S H Sindrup
Journal:  Neurology       Date:  2002-05-14       Impact factor: 9.910

8.  Neuropathy associated with hyperlipidemia.

Authors:  P G McManis; A J Windebank; M Kiziltan
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

9.  A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy.

Authors:  R A C Hughes; T Umapathi; I A Gray; N A Gregson; M Noori; A S Pannala; A Proteggente; A V Swan
Journal:  Brain       Date:  2004-06-16       Impact factor: 13.501

10.  Plantar nerve AP and skin biopsy in sensory neuropathies with normal routine conduction studies.

Authors:  D N Herrmann; M L Ferguson; V Pannoni; R L Barbano; M Stanton; E L Logigian
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

View more
  12 in total

Review 1.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

Review 2.  Acquired neuropathies.

Authors:  Pierre Lozeron; Jean-Marc Trocello; Nathalie Kubis
Journal:  J Neurol       Date:  2013-06-16       Impact factor: 4.849

Review 3.  Chronic idiopathic axonal polyneuropathy: a systematic review.

Authors:  Panagiotis Zis; Ptolemaios Georgios Sarrigiannis; Dasappaiah Ganesh Rao; Channa Hewamadduma; Marios Hadjivassiliou
Journal:  J Neurol       Date:  2016-03-09       Impact factor: 4.849

4.  Axonal neuropathy in female carriers of the fragile X premutation with fragile x-associated tremor ataxia syndrome.

Authors:  Suresh Ram; Inoka A Devapriya; Grace Fenton; Lindsey Mcvay; Danh V Nguyen; Flora Tassone; Ricardo A Maselli; Randi J Hagerman
Journal:  Muscle Nerve       Date:  2015-08       Impact factor: 3.217

5.  Association of comorbidities with increasing severity of peripheral neuropathy in diabetes mellitus.

Authors:  Shafina Sachedina; Cory Toth
Journal:  World J Diabetes       Date:  2013-08-15

Review 6.  Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Kyung Ae Lee; Tae Sun Park; Heung Yong Jin
Journal:  Endocrine       Date:  2020-09-07       Impact factor: 3.633

Review 7.  Detrimental impact of hyperlipidemia on the peripheral nervous system: A novel target of medical epidemiological and fundamental research study.

Authors:  Song Wu; Xu Cao; Rongzhen He; Kun Xiong
Journal:  Neural Regen Res       Date:  2012-02-15       Impact factor: 5.135

8.  Critical illness polyneuropathy (CIP) in neurological early rehabilitation: clinical and neurophysiological features.

Authors:  Simone B Schmidt; Jens D Rollnik
Journal:  BMC Neurol       Date:  2016-12-15       Impact factor: 2.474

9.  Chronic idiopathic axonal polyneuropathy is associated with the metabolic syndrome.

Authors:  Nora A Visser; Alexander F J E Vrancken; Yvonne T van der Schouw; Leonard H van den Berg; Nicolette C Notermans
Journal:  Diabetes Care       Date:  2012-11-30       Impact factor: 19.112

Review 10.  The epidemiology and risk factors of chronic polyneuropathy.

Authors:  Rens Hanewinckel; Marieke van Oijen; M Arfan Ikram; Pieter A van Doorn
Journal:  Eur J Epidemiol       Date:  2015-12-23       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.